Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) has secured a new U.S. patent for its bioengineered esophagus, expanding its intellectual property portfolio. The patent, titled "Tubular Prostheses (Esophagus)," provides protection until 2041 and covers key structural and mechanical attributes for esophageal replacement.
The company has now secured patent coverage for bioengineered trachea, esophagus, and urinary conduits across multiple regions including the United States, Europe, Canada, and Australia. These advanced tissue constructs have been evaluated in early preclinical models, with plans for future testing in large animal models.
The technology is part of Humacyte's broader pipeline, which includes ATEV™, CTEV, and BioVascular Pancreas™ (BVP™), all utilizing the same bioengineering platform as their Symvess™ product. The company plans to seek corporate partnerships to accelerate development.
Humacyte (Nasdaq: HUMA) has published promising preclinical data in JACC: Basic to Translational Science regarding their coronary tissue engineered vessel (CTEV) for coronary artery bypass grafting (CABG). The study, conducted on five adult baboons, demonstrated that all CTEVs remained patent throughout the 6-month study period.
Key findings show the CTEV successfully recellularized with host cells and adapted to match native artery size. The company plans to advance to first-in-human trials, with an IND application to the FDA expected in Q4 2025. This innovation could potentially address the limitations of current saphenous vein grafts, which show approximately 50% failure rate at 10 years.
Humacyte (Nasdaq: HUMA) announced the publication of clinical outcomes in the Journal of Vascular Surgery for patients treated with Symvess™, their FDA-approved bioengineered human tissue vascular conduit. The study focused on 12 patients with hospital-acquired vascular complications from their V005 pivotal Phase 2/3 clinical trial.
Key results showed 92% secondary patency (blood flow) at an average follow-up of 23.3 months, with 100% limb salvage and zero conduit infections. The patients required arterial repair due to various complications including vascular interventions, tumor resections, and orthopedic surgery injuries. Symvess received full FDA approval in December 2024 for use in adults requiring urgent revascularization for extremity arterial injury.
Humacyte (Nasdaq: HUMA) reported Q2 2025 financial results and business updates. The company generated $301,000 in revenue for Q2 2025 and $818,000 for H1 2025. Key highlights include 82 civilian hospitals now approved to purchase Symvess™, and ECAT approval making the product available to 35 Military Treatment Facilities and 160 VA hospitals.
The company implemented cost reduction measures, including a 30-employee workforce reduction, expecting to save approximately $50 million through 2026. Q2 resulted in a net loss of $37.7 million, with cash position of $88.4 million as of June 30, 2025. July product sales of $0.3 million exceeded total H1 sales, showing commercial momentum.
Clinical progress includes positive V007 Phase 3 trial results for dialysis access, particularly strong in high-risk subgroups, and achievement of 100-patient enrollment in the V012 Phase 3 trial.
Humacyte (Nasdaq: HUMA), a clinical-stage biotechnology company focused on developing bioengineered human tissue, has scheduled its Q2 2025 financial results and corporate update for August 11, 2025, at 8:00 AM ET.
The company will host a conference call and webcast, accessible to U.S. investors at 1-877-704-4453 and international investors at 1-201-389-0920 using Conference ID 13754596. The webcast will be available 15 minutes before the call and remain accessible for at least 30 days afterward on the company's investor relations website.
Humacyte (Nasdaq: HUMA) announced its first sale of Symvess to a U.S. Military Treatment Facility, following its recent Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. The facility serves approximately 200,000 active-duty service personnel, retirees, and family members.
Symvess, an acellular tissue engineered vessel approved by the FDA in December 2024 for extremity vascular trauma, is now available to approximately 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals through the ECAT system, which provides DOD and other federal agencies access to medical products.
Humacyte (Nasdaq: HUMA) has received Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency for its Symvess product. This approval enables healthcare professionals at Department of Defense (DOD) and Veterans Affairs facilities to access Symvess for treating military service members, veterans, and other patients.
Symvess, an acellular tissue engineered vessel, received FDA approval in December 2024 for extremity vascular trauma indication. The ECAT system integration represents a significant milestone in making the product accessible to military healthcare providers. However, for uses beyond the FDA-approved indication, Symvess remains investigational and requires further regulatory approval.
Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company focused on developing universally implantable, bioengineered human tissues, has announced its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference. The event will take place at the Nasdaq World Headquarters in New York on May 20, 2025.
The company's Founder, President, and CEO, Laura Niklason, M.D., Ph.D., will participate in a fireside chat at 12:30 p.m. EST. Management will also be available for one-on-one meetings. A webcast replay will be accessible through the Events & Presentations section of Humacyte's website.